Aleix Prat

Research interests

Publications

• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00051-7

• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203690

• High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  Nature Communications · 2022 · https://doi.org/10.1038/s41467-022-32828-6

• Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00034-6

• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  npj Breast Cancer · 2021 · https://doi.org/10.1038/s41523-020-00208-2

• Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30642-2

• Immune-related adverse events of checkpoint inhibitors

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0160-6

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  JNCI Journal of the National Cancer Institute · 2019 · https://doi.org/10.1093/jnci/djz042

• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy192

• Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

  Cancer Research · 2017 · https://doi.org/10.1158/0008-5472.can-16-2717

• Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

  Cancer Research · 2017 · https://doi.org/10.1158/0008-5472.can-16-3556

• HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30021-9

• Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

  JAMA Oncology · 2016 · https://doi.org/10.1001/jamaoncol.2016.0922

• PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

  Science Translational Medicine · 2015 · https://doi.org/10.1126/scitranslmed.aaa4442

• Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer

  Bioinformatics · 2015 · https://doi.org/10.1093/bioinformatics/btv693

• Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-14-3081

• MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11

  Nature Communications · 2013 · https://doi.org/10.1038/ncomms2393

• Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

  Cell Reports · 2013 · 10.1016/j.celrep.2013.08.022

• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt419

• PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

  Cancer Discovery · 2012 · https://doi.org/10.1158/2159-8290.cd-11-0348

• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients

  Proceedings of the National Academy of Sciences · 2011 · https://doi.org/10.1073/pnas.1014835108

• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

  Breast Cancer Research · 2010 · 10.1186/bcr2635

Current projects

No projects listed.